Traws Pharma (NASDAQ:TRAW) Announces Earnings Results

Traws Pharma (NASDAQ:TRAW) posted its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share for the quarter, FiscalAI reports. Traws Pharma had a negative return on equity of 1,812.48% and a net margin of 3,028.25%.

Traws Pharma Price Performance

Shares of NASDAQ:TRAW traded up $0.40 during trading on Friday, reaching $2.17. 8,097,342 shares of the stock were exchanged, compared to its average volume of 464,937. Traws Pharma has a 1-year low of $0.97 and a 1-year high of $19.44. The stock has a fifty day moving average of $2.28 and a two-hundred day moving average of $1.77. The firm has a market cap of $15.46 million, a price-to-earnings ratio of 0.02 and a beta of 1.73.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Two Sigma Investments LP lifted its stake in shares of Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after buying an additional 5,955 shares in the last quarter. Vestal Point Capital LP lifted its position in Traws Pharma by 133.3% in the 1st quarter. Vestal Point Capital LP now owns 175,000 shares of the company’s stock valued at $402,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Traws Pharma during the 1st quarter valued at about $759,000. Institutional investors and hedge funds own 7.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Traws Pharma in a research note on Thursday, October 30th. Wall Street Zen upgraded shares of Traws Pharma to a “hold” rating in a research report on Saturday, November 1st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Traws Pharma has an average rating of “Sell”.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.